Stockhub

Arbutus Biopharma Corporation: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

15 August 2022

11 August 2022

26 July 2022

  • curprev 12:3512:35, 26 July 2022‎ Chris talk contribs‎ 1,620 bytes +1,620‎ Created page with "Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-a..." Tag: Visual edit
Retrieved from ‘https://stockhub.co/research/Arbutus_Biopharma_Corporation’